Skip to content
OpenCapital
Get started

Entrada Therapeutics TRDA Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$1.3MMiss by $6.1M
EPS-$0.94Beat by $0.38
Revenue estimate$7.4M
EPS estimate-$1.32

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$2.2M
EPS estimate-$1.05

Versus estimates

Revenue

Q1 2026$875.0KMiss by $2.0M
Q4 2025$1.3MMiss by $6.1M
Q3 2025$1.6MMiss by $6.9MQ2 2025$2.0MMiss by $5.9MQ1 2025$20.6MBeat by $10.8MQ4 2024$37.4MBeat by $24.3M

Diluted EPS

Q1 2026-$0.95Beat by $0.11
Q4 2025-$0.94Beat by $0.38
Q3 2025-$1.06Miss by $0.02Q2 2025-$1.04Miss by $0.18Q1 2025-$0.42Beat by $0.36Q4 2024$0.03Beat by $0.69

Ask the moment Entrada Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Entrada Therapeutics report Q4 2025 earnings?
Entrada Therapeutics (TRDA) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Entrada Therapeutics's Q4 2025 revenue and EPS?
Entrada Therapeutics reported revenue of $1.3M and eps of $-0.94 for Q4 2025.
Did Entrada Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $7.4M by $6.1M. EPS beat the consensus estimate of $-1.32 by $0.38.
How did Entrada Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 96.5% from $37.4M a year earlier.
Where can I find Entrada Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001689375-26-000009) and the 10-K periodic report (0001689375-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.